Treatment outcome of 301 aplastic anemia patients in China: a 10-year follow-up and real-world data from single institute experience

References

• Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509–2519.
   PubMed Web of Science ®Google Scholar
• Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German aplastic anemia study group. N Engl J Med. 1991;324(19):1297–1304.
   PubMed Web of Science ®Google Scholar
• Speck B, Gluckman E, Haak HL, et al. Treatment of aplastic anaemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions. Lancet. 1977;2(8049):1145–1148.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) working party on severe aplastic anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood. 2000;95(6):1931–1934.
   PubMed Web of Science ®Google Scholar
• Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007;92(1):11–18.
   PubMed Web of Science ®Google Scholar
• Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187–207.
   PubMed Web of Science ®Google Scholar
• Frytak JR, Henk HJ, De Castro CM, et al. Estimation of economic costs associated with transfusion dependence in adults with MDS. Curr Med Res Opin. 2009;25(8):1941–1951.
   PubMed Web of Science ®Google Scholar
• Vaht K, Goransson M, Carlson K, et al. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000−2011. Haematologica. 2017;102(10):1683–1690.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Socie G, Lanino E, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematologica. 2010;95(6):976–982.
   PubMed Web of Science ®Google Scholar
• Marsh JC, Pearce RM, Koh MB, et al. Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British society for blood and marrow transplantation. Bone Marrow Transplant. 2014;49(1):42–48.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Giammarco S, Sica S. Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia. Int J Hematol. 2016;104(2):168–174.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Xu Z, Zhang Y, et al. First-line choice for severe aplastic anemia in children: transplantation from a haploidentical donor vs immunosuppressive therapy. Clin Transplant. 2018;32(2). doi:https://doi.org/10.1111/ctr.13179 [Epub 2018 Jan 3].
   Google Scholar
• Ye L, Zhang F, Kojima S. Current insights into the treatments of severe aplastic anemia in China. Int J Hematol. 2020;112(3):292–299.
   PubMed Web of Science ®Google Scholar
• Yoshida N, Kobayashi R, Yabe H, et al. First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy. Haematologica. 2014;99(12):1784–1791.
   PubMed Web of Science ®Google Scholar
• Tichelli A, Socie G, Henry-amar M, et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European group for blood and marrow transplantation severe aplastic anaemia working party. Ann Intern Med. 1999;130(3):193–201.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A. Guidelines for the treatment of severe aplastic anemia. Working Party on Severe Aplastic Anemia (WPSAA) of the European group of Bone Marrow Transplantation (EBMT). Haematologica. 1994;79(5):438–444.
   PubMed Web of Science ®Google Scholar
• Marsh JC, Ball SE, Darbyshire P, et al. Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol. 2003;123(5):782–801.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129(11):1428–1436.
   PubMed Web of Science ®Google Scholar
• Gupta V, Eapen M, Brazauskas R, et al. Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica. 2010;95(12):2119–2125.
   PubMed Web of Science ®Google Scholar
• Maury S, Bacigalupo A, Anderlini P, et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica. 2009;94(9):1312–1315.
   PubMed Web of Science ®Google Scholar
• Devillier R, Dalle JH, Kulasekararaj A, et al. Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French society of bone marrow transplantation and cell therapies and the EBMT severe aplastic anemia working party. Haematologica. 2016;101(7):884–890.
   PubMed Web of Science ®Google Scholar
• Ades L, Mary JY, Robin M, et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood. 2004;103(7):2490–2497.
   PubMed Web of Science ®Google Scholar
• Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367(1):11–19.
   PubMed Web of Science ®Google Scholar
• Lengline E, Drenou B, Peterlin P, et al. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French reference center for aplastic anemia. Haematologica. 2018;103(2):212–220.
   PubMed Web of Science ®Google Scholar
• Cheng H, Wang X, Zhou D, et al. Eltrombopag combined with cyclosporine may have an effect on very severe aplastic anemia. Ann Hematol. 2019;98(8):2009–2011.
   PubMed Web of Science ®Google Scholar
• Bartoszko J, Panzarella T, Lau A, et al. Effect of red blood cell transfusion dependence on the natural history of myeloproliferative neoplasm-associated myelofibrosis. Clin Lymphoma Myeloma Leuk. 2015;15(11):e151–e156.
   PubMedGoogle Scholar
• Braga Lemos M, Rodrigues SR, Schroeder T, et al. Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: a systematic literature review and meta-analysis. Eur J Haematol. 2021;107(1):3–23.
   PubMed Web of Science ®Google Scholar
• Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) severe aplastic anaemia working party. Blood. 1999;93(7):2191–2195.
   PubMed Web of Science ®Google Scholar